Jul. 15 at 2:19 PM
$PROK This could Easliy make you Wealthy. ProKidney’s cell therapy, REACT® (rilparencel), aims to delay or prevent the need for dialysis. By preserving remaining kidney function, it offers substantial long-term cost savings compared to traditional dialysis, which costs Medicare an average of
$93,000 to
$114,000 per patient annually.For the U.S. healthcare system, successfully avoiding or delaying the need for End-Stage Renal Disease (ESRD) care yields immense financial benefits:High Dialysis Burden: Dialysis is the single most expensive treatment for people with kidney disease under Medicare. Patients can spend 5 to 10 years on dialysis on average, and total expenditures can soar up to
$238,000 in their first year for privately insured patients.Cost Savings Potential:
Timeline: ProKidney is currently advancing REACT® through Phase 3 clinical trials, with commercial availability potentially targeted for 2028 if regulatory approvals are secured.
$MRK,
$ABBV,
$LLY
